Jennifer R Lane

US Patent:

7429462, Sep 30, 2008

Filed:

Feb 15, 2007

Appl. No.:

11/706809

Inventors:

Carol Ann Morris - Duluth GA, US
Fiona Patricia Carney - Atlanta GA, US
Jennifer Dawn Lane - Stone Mountain GA, US

Assignee:

Novartis AG - Basel

International Classification:

C12Q 1/54

US Classification:

435 14

Abstract:

The invention provides an in vivo screening assay and an in vitro screening assay for rapid screening of diabetes. A method of the invention includes determining a first glucose concentration in an ocular fluid of a patient; administering orally a load of carbohydrate to the patient; determining a second glucose concentration in an ocular fluid of the patient at a period of time of less than 50 minutes after orally administering of the load of carbohydrate; comparing the second glucose concentration with the first glucose concentration to determine if the patient is likely to be a diabetic. The method of the invention is performed by using a kit of the invention. The kit comprises: (1) a glucose-sensing ophthalmic device and instructions for using the glucose-sensing ophthalmic device to screen for diabetes; or (2) two or more tear-collecting devices, and a testing agent composition which specifically reacts with glucose to form a detectable signal. The glucose-sensing ophthalmic device comprises a testing agent composition which specifically and reversibly interacts with glucose to form a detectable optical signal which changes in a concentration-dependent manner.

US Patent:

20050038329, Feb 17, 2005

Filed:

Nov 12, 2003

Appl. No.:

10/706208

Inventors:

Carol Morris - Duluth GA, US
Fiona Carney - Atlanta GA, US
Jennifer Lane - Stone Mountain GA, US

International Classification:

A61B005/00
C12Q001/54

US Classification:

600319000, 435014000

Abstract:

The invention provides an in vivo screening assay and an in vitro screening assay for rapid screening of diabetes. A method of the invention includes determining a first glucose concentration in an ocular fluid of a patient; administering orally a load of carbohydrate to the patient; determining a second glucose concentration in an ocular fluid of the patient at a period of time of less than 50 minutes after orally administering of the load of carbohydrate; comparing the second glucose concentration with the first glucose concentration to determine if the patient is likely to be a diabetic. The method of the invention is performed by using a kit of the invention. The kit comprises: (1) a glucose-sensing ophthalmic device and instructions for using the glucose-sensing ophthalmic device to screen for diabetes; or (2) two or more tear-collecting devices, and a testing agent composition which specifically reacts with glucose to form a detectable signal. The glucose-sensing ophthalmic device comprises a testing agent composition which specifically and reversibly interacts with glucose to form a detectable optical signal which changes in a concentration-dependent manner.